Title : Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.

Pub. Date : 2001 May

PMID : 11422413






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Cost per QALY gained by the treatment with high-dose melphalan and autologous blood stem cell support was estimated at NOK 249,000 (USD 27,000). Melphalan serine/threonine/tyrosine kinase 1 Homo sapiens